Chronic diseases that affect our society are made more complex by comorbidities and are poorly managed by the current pharmacology. While all present inflammatory etiopathogeneses, there is an unmet need for better clinical management of these diseases and their multiple symptoms. We discuss here an innovative approach based on the biology of the resolution of inflammation. Studying endogenous pro-resolving peptide and lipid mediators, how they are formed, and which target they interact with, can offer innovative options through augmenting the expression or function of pro-resolving pathways or mimicking their actions with novel targeted molecules. In all cases, resolution offers innovation for the treatment of the primary cause of a given disease and/or for the management of its comorbidities, ultimately improving patient quality of life. By implementing resolution pharmacology, we harness the whole physiology of inflammation, with the potential to bring a marked change in the management of inflammatory conditions.

中文翻译：

---

解决药理学：专注于促进炎症治疗创新的膜联蛋白 A1 和脂质介质的解决

影响我们社会的慢性疾病因合并症而变得更加复杂，并且当前的药理学管理不善。尽管所有疾病都存在炎症病因，但对这些疾病及其多种症状进行更好的临床管理的需求尚未得到满足。我们在这里讨论一种基于炎症消退生物学的创新方法。研究内源性促解析肽和脂质介质、它们是如何形成的以及它们与哪些靶标相互作用，可以通过增强促解析途径的表达或功能或用新的靶向分子模拟它们的作用来提供创新的选择。在所有情况下，解决方案都为治疗特定疾病的主要原因和/或管理其合并症提供了创新，最终提高了患者的生活质量。通过实施解析药理学，我们利用炎症的整个生理学，有可能为炎症性疾病的治疗带来显着的变化。